Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29119898 | 0.86 | NTRK1 (0.56) | FYNMKNK1 | |
| SCHEMBL2949835 | 0.84 | FYN (0.57) | FYNMKNK1 | |
| SCHEMBL2945041 | 0.80 | FYN (0.56) | FYNMKNK1 | |
| SCHEMBL2946667 | 0.80 | FYN (0.50) | FYNMKNK1 | |
| SCHEMBL20485717 | 0.79 | FYN (1.00) | FYN | |
| SCHEMBL3033296 | 0.78 | FYN (0.63) | FYNMKNK1 | |
| SCHEMBL3033593 | 0.78 | FYN (0.88) | FYN | |
| SCHEMBL477064 | 0.76 | DYRK1A (0.70) | FYNMKNK1 | |
| SCHEMBL3037756 | 0.76 | FYN (0.61) | FYNMKNK1 | |
| SCHEMBL3038068 | 0.76 | FYN (0.72) | FYNMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | FYN 3/4885MKNK1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.